Dual action antifungal small molecule modulates multidrug efflux and TOR signaling

Tanvi Shekhar-Guturja, G. M.Kamal B. Gunaherath, E. M.Kithsiri Wijeratne, Jean Philippe Lambert, Anna F. Averette, Soo Chan Lee, Taeyup Kim, Yong Sun Bahn, Farida Tripodi, Ron Ammar, Katja Döhl, Karolina Niewola-Staszkowska, Lutz Schmitt, Robbie J. Loewith, Frederick PRoth, Dominique Sanglard, David Andes, Corey Nislow, Paola Coccetti, Anne Claude GingrasJoseph Heitman, Leslie Gunatilaka, Leah ECowen

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

There is an urgent need for new strategies to treat invasive fungal infections, which are a leading cause of human mortality. Here, we establish two activities of the natural product beauvericin, which potentiates the activity of the most widely deployed class of antifungal against the leading human fungal pathogens, blocks the emergence of drug resistance, and renders antifungal-resistant pathogens responsive to treatment in mammalian infection models. Harnessing genome sequencing of beauvericin-resistant mutants, affinity purification of a biotinylated beauvericin analog, and biochemical and genetic assays reveals that beauvericin blocks multidrug efflux and inhibits the global regulator TORC1 kinase, thereby activating the protein kinase CK2 and inhibiting the molecular chaperone Hsp90. Substitutions in the multidrug transporter Pdr5 that enable beauvericin efflux impair antifungal efflux, thereby impeding resistance to the drug combination. Thus, dual targeting of multidrug efflux and TOR signaling provides a powerful, broadly effective therapeutic strategy for treating fungal infectious disease that evades resistance.

Original languageEnglish (US)
Pages (from-to)867-875
Number of pages9
JournalNature Chemical Biology
Volume12
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Fungal Drug Resistance
Casein Kinase II
Molecular Chaperones
Disease Resistance
Mycoses
Drug Combinations
Biological Products
Communicable Diseases
Molecular Biology
Phosphotransferases
beauvericin
Genome
Mortality
Infection
Therapeutics
mechanistic target of rapamycin complex 1
Invasive Fungal Infections

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

Shekhar-Guturja, T., Gunaherath, G. M. K. B., Wijeratne, E. M. K., Lambert, J. P., Averette, A. F., Lee, S. C., ... ECowen, L. (2016). Dual action antifungal small molecule modulates multidrug efflux and TOR signaling. Nature Chemical Biology, 12(10), 867-875. https://doi.org/10.1038/nchembio.2165

Dual action antifungal small molecule modulates multidrug efflux and TOR signaling. / Shekhar-Guturja, Tanvi; Gunaherath, G. M.Kamal B.; Wijeratne, E. M.Kithsiri; Lambert, Jean Philippe; Averette, Anna F.; Lee, Soo Chan; Kim, Taeyup; Bahn, Yong Sun; Tripodi, Farida; Ammar, Ron; Döhl, Katja; Niewola-Staszkowska, Karolina; Schmitt, Lutz; Loewith, Robbie J.; PRoth, Frederick; Sanglard, Dominique; Andes, David; Nislow, Corey; Coccetti, Paola; Gingras, Anne Claude; Heitman, Joseph; Gunatilaka, Leslie; ECowen, Leah.

In: Nature Chemical Biology, Vol. 12, No. 10, 01.10.2016, p. 867-875.

Research output: Contribution to journalArticle

Shekhar-Guturja, T, Gunaherath, GMKB, Wijeratne, EMK, Lambert, JP, Averette, AF, Lee, SC, Kim, T, Bahn, YS, Tripodi, F, Ammar, R, Döhl, K, Niewola-Staszkowska, K, Schmitt, L, Loewith, RJ, PRoth, F, Sanglard, D, Andes, D, Nislow, C, Coccetti, P, Gingras, AC, Heitman, J, Gunatilaka, L & ECowen, L 2016, 'Dual action antifungal small molecule modulates multidrug efflux and TOR signaling', Nature Chemical Biology, vol. 12, no. 10, pp. 867-875. https://doi.org/10.1038/nchembio.2165
Shekhar-Guturja T, Gunaherath GMKB, Wijeratne EMK, Lambert JP, Averette AF, Lee SC et al. Dual action antifungal small molecule modulates multidrug efflux and TOR signaling. Nature Chemical Biology. 2016 Oct 1;12(10):867-875. https://doi.org/10.1038/nchembio.2165
Shekhar-Guturja, Tanvi ; Gunaherath, G. M.Kamal B. ; Wijeratne, E. M.Kithsiri ; Lambert, Jean Philippe ; Averette, Anna F. ; Lee, Soo Chan ; Kim, Taeyup ; Bahn, Yong Sun ; Tripodi, Farida ; Ammar, Ron ; Döhl, Katja ; Niewola-Staszkowska, Karolina ; Schmitt, Lutz ; Loewith, Robbie J. ; PRoth, Frederick ; Sanglard, Dominique ; Andes, David ; Nislow, Corey ; Coccetti, Paola ; Gingras, Anne Claude ; Heitman, Joseph ; Gunatilaka, Leslie ; ECowen, Leah. / Dual action antifungal small molecule modulates multidrug efflux and TOR signaling. In: Nature Chemical Biology. 2016 ; Vol. 12, No. 10. pp. 867-875.
@article{f627d800e2ce4178b2c5efd5e8fbfef2,
title = "Dual action antifungal small molecule modulates multidrug efflux and TOR signaling",
abstract = "There is an urgent need for new strategies to treat invasive fungal infections, which are a leading cause of human mortality. Here, we establish two activities of the natural product beauvericin, which potentiates the activity of the most widely deployed class of antifungal against the leading human fungal pathogens, blocks the emergence of drug resistance, and renders antifungal-resistant pathogens responsive to treatment in mammalian infection models. Harnessing genome sequencing of beauvericin-resistant mutants, affinity purification of a biotinylated beauvericin analog, and biochemical and genetic assays reveals that beauvericin blocks multidrug efflux and inhibits the global regulator TORC1 kinase, thereby activating the protein kinase CK2 and inhibiting the molecular chaperone Hsp90. Substitutions in the multidrug transporter Pdr5 that enable beauvericin efflux impair antifungal efflux, thereby impeding resistance to the drug combination. Thus, dual targeting of multidrug efflux and TOR signaling provides a powerful, broadly effective therapeutic strategy for treating fungal infectious disease that evades resistance.",
author = "Tanvi Shekhar-Guturja and Gunaherath, {G. M.Kamal B.} and Wijeratne, {E. M.Kithsiri} and Lambert, {Jean Philippe} and Averette, {Anna F.} and Lee, {Soo Chan} and Taeyup Kim and Bahn, {Yong Sun} and Farida Tripodi and Ron Ammar and Katja D{\"o}hl and Karolina Niewola-Staszkowska and Lutz Schmitt and Loewith, {Robbie J.} and Frederick PRoth and Dominique Sanglard and David Andes and Corey Nislow and Paola Coccetti and Gingras, {Anne Claude} and Joseph Heitman and Leslie Gunatilaka and Leah ECowen",
year = "2016",
month = "10",
day = "1",
doi = "10.1038/nchembio.2165",
language = "English (US)",
volume = "12",
pages = "867--875",
journal = "Nature Chemical Biology",
issn = "1552-4450",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Dual action antifungal small molecule modulates multidrug efflux and TOR signaling

AU - Shekhar-Guturja, Tanvi

AU - Gunaherath, G. M.Kamal B.

AU - Wijeratne, E. M.Kithsiri

AU - Lambert, Jean Philippe

AU - Averette, Anna F.

AU - Lee, Soo Chan

AU - Kim, Taeyup

AU - Bahn, Yong Sun

AU - Tripodi, Farida

AU - Ammar, Ron

AU - Döhl, Katja

AU - Niewola-Staszkowska, Karolina

AU - Schmitt, Lutz

AU - Loewith, Robbie J.

AU - PRoth, Frederick

AU - Sanglard, Dominique

AU - Andes, David

AU - Nislow, Corey

AU - Coccetti, Paola

AU - Gingras, Anne Claude

AU - Heitman, Joseph

AU - Gunatilaka, Leslie

AU - ECowen, Leah

PY - 2016/10/1

Y1 - 2016/10/1

N2 - There is an urgent need for new strategies to treat invasive fungal infections, which are a leading cause of human mortality. Here, we establish two activities of the natural product beauvericin, which potentiates the activity of the most widely deployed class of antifungal against the leading human fungal pathogens, blocks the emergence of drug resistance, and renders antifungal-resistant pathogens responsive to treatment in mammalian infection models. Harnessing genome sequencing of beauvericin-resistant mutants, affinity purification of a biotinylated beauvericin analog, and biochemical and genetic assays reveals that beauvericin blocks multidrug efflux and inhibits the global regulator TORC1 kinase, thereby activating the protein kinase CK2 and inhibiting the molecular chaperone Hsp90. Substitutions in the multidrug transporter Pdr5 that enable beauvericin efflux impair antifungal efflux, thereby impeding resistance to the drug combination. Thus, dual targeting of multidrug efflux and TOR signaling provides a powerful, broadly effective therapeutic strategy for treating fungal infectious disease that evades resistance.

AB - There is an urgent need for new strategies to treat invasive fungal infections, which are a leading cause of human mortality. Here, we establish two activities of the natural product beauvericin, which potentiates the activity of the most widely deployed class of antifungal against the leading human fungal pathogens, blocks the emergence of drug resistance, and renders antifungal-resistant pathogens responsive to treatment in mammalian infection models. Harnessing genome sequencing of beauvericin-resistant mutants, affinity purification of a biotinylated beauvericin analog, and biochemical and genetic assays reveals that beauvericin blocks multidrug efflux and inhibits the global regulator TORC1 kinase, thereby activating the protein kinase CK2 and inhibiting the molecular chaperone Hsp90. Substitutions in the multidrug transporter Pdr5 that enable beauvericin efflux impair antifungal efflux, thereby impeding resistance to the drug combination. Thus, dual targeting of multidrug efflux and TOR signaling provides a powerful, broadly effective therapeutic strategy for treating fungal infectious disease that evades resistance.

UR - http://www.scopus.com/inward/record.url?scp=84984624652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984624652&partnerID=8YFLogxK

U2 - 10.1038/nchembio.2165

DO - 10.1038/nchembio.2165

M3 - Article

C2 - 27571477

AN - SCOPUS:84984624652

VL - 12

SP - 867

EP - 875

JO - Nature Chemical Biology

JF - Nature Chemical Biology

SN - 1552-4450

IS - 10

ER -